Avecho Biotechnology Limited

ASX:AVE Stock Report

Market Cap: AU$9.5m

Avecho Biotechnology Management

Management criteria checks 4/4

Avecho Biotechnology's CEO is Paul Gavin, appointed in May 2020, has a tenure of 4.08 years. total yearly compensation is A$291.80K, comprised of 77.8% salary and 22.2% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth A$32.58K. The average tenure of the management team and the board of directors is 4.1 years and 6.8 years respectively.

Key information

Paul Gavin

Chief executive officer

AU$291.8k

Total compensation

CEO salary percentage77.8%
CEO tenure4.1yrs
CEO ownership0.3%
Management average tenure4.1yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

May 31
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Nov 04
Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Jul 14
We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Mar 23
We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Dec 08
We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

CEO Compensation Analysis

How has Paul Gavin's remuneration changed compared to Avecho Biotechnology's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023AU$292kAU$227k

-AU$3m

Sep 30 2023n/an/a

-AU$4m

Jun 30 2023n/an/a

-AU$4m

Mar 31 2023n/an/a

-AU$3m

Dec 31 2022AU$355kAU$227k

-AU$2m

Sep 30 2022n/an/a

-AU$2m

Jun 30 2022n/an/a

-AU$2m

Mar 31 2022n/an/a

-AU$3m

Dec 31 2021AU$477kAU$227k

-AU$3m

Sep 30 2021n/an/a

-AU$3m

Jun 30 2021n/an/a

-AU$3m

Mar 31 2021n/an/a

-AU$3m

Dec 31 2020AU$497kAU$231k

-AU$3m

Sep 30 2020n/an/a

-AU$2m

Jun 30 2020n/an/a

-AU$2m

Mar 31 2020n/an/a

-AU$739k

Dec 31 2019AU$235kAU$200k

AU$850k

Sep 30 2019n/an/a

AU$504k

Jun 30 2019n/an/a

AU$158k

Mar 31 2019n/an/a

-AU$2m

Dec 31 2018AU$231kAU$200k

-AU$4m

Jun 30 2018n/an/a

-AU$6m

Mar 31 2018n/an/a

-AU$7m

Dec 31 2017AU$238kAU$200k

-AU$9m

Compensation vs Market: Paul's total compensation ($USD194.56K) is below average for companies of similar size in the Australian market ($USD299.00K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


CEO

Paul Gavin

4.1yrs

Tenure

AU$291,796

Compensation

Dr. Paul Gavin, BSc (Hons), PhD serves as Chief Executive Officer of Avecho Biotechnology Limited (formerly known as Phosphagenics Limited) since May 01, 2020 and served as its Chief Scientific Officer unt...


Leadership Team

NamePositionTenureCompensationOwnership
Paul Gavin
Chief Executive Officer4.1yrsAU$291.80k0.34%
A$ 32.6k
Roksan Libinaki
Chief Operating Officer4.1yrsAU$242.70k0.35%
A$ 33.3k
Melanie Leydin
Company Secretary & CFO5.5yrsno datano data

4.1yrs

Average Tenure

Experienced Management: AVE's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ross Murdoch
Independent Director9.2yrsAU$65.32k0.11%
A$ 10.0k
Gregory Collier
Independent Non-Executive Chairman9.2yrsAU$115.10k0.37%
A$ 35.0k
Simon West
Chairman of Scientific Advisory Boardno datano datano data
Matthew McNamara
Independent Non-Executive Director4.4yrsAU$65.32k0.053%
A$ 5.0k
Katherine Connell
Non-Executive Directorless than a yearno datano data

6.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: AVE's board of directors are considered experienced (6.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.